The precursor to BioCurate was launched in June 2016 with the ‘working title’ of M2 Venture Catalyst. Since then, BioCurate Pty Ltd has been incorporated and commenced operations in early 2017.
BioCurate is a venture catalyst, a new model that is consistent with emerging leading-edge global practice. The company’s key focus and objective is to translate drug discoveries to a form which attracts investors or other commercialisation partners. This will be done through the provision of independent specialist expertise in drug development and commercialization, and the required funding targeted specifically at this critical phase. BioCurate will work across different therapeutic modalities including small molecules, biologics and antibodies.
BioCurate is not a venture fund - success will be gauged by the number of follow on investments that are able to be made, not by the quantum of the eventual exits that will occur. BioCurate therefore seeks to create a whole network of commercialisable therapeutic discoveries and so its activities will complement rather than compete with the VC funds.
BioCurate is a joint venture of the University of Melbourne and Monash University, supported by the Victorian State Government. Its founders are Australia’s two leading biomedical universities both located in Melbourne. Together these Universities are placed in the world’s top 10 in the therapeutic areas of immunology, oncology, paediatrics, neurosciences, and infectious diseases.
Their historic collaboration to form BioCurate will unlock the combined exceptional biomedical research strengths in Melbourne, enabling significant new discoveries to be translated more rapidly into new medicines. The potential health and economic benefits that will flow to Victoria and Australia are enormous.
BioCurate is operationally independent of the Universities and has an independent Board Chair, the Hon John Brumby. Mr Brumby is an eminent Australian with demonstrated leadership and commitment to innovation. He will be supported by a highly experienced Board of Directors with specialist backgrounds in biotechnology and/or drug development commercialization, investment and corporate governance.
BioCurate is a joint venture of Monash University and the University of Melbourne.